News >

Future of Bladder Cancer Care to Include Immunotherapy Combos

Danielle Bucco
Published: Wednesday, Nov 29, 2017

It is important to keep in mind that rational combinations can be evaluated in the non-muscle invasive disease space. There are thoughts about designing clinical trials of BCG combined with other immunotherapy agents, especially in the BCG relapsing and unresponsive NMIBC space. For now, BCG does continue to have an established role, especially in patients with BCG-naïve non-muscle invasive high-grade disease. 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication